DGX vs DVA
Quest Diagnostics Inc. and Davita Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | DGX | DVA |
|---|---|---|
| Revenue | $11.0B | $13.6B |
| Net income | $992.0M | $746.8M |
| Gross margin | 33.2% | — |
| Net margin | 9.0% | 5.5% |
| Return on equity | 14.2% | 159.1% |
| Diluted EPS | $8.75 | $9.84 |
| Dividend / share | $1.80 | — |
| Payout ratio | 35.6% | 0.0% |
| Free cash flow | $1.4B | $1.3B |
| Equity | $7.2B | $-651.1M |
| Net debt / equity | 0.73× | 69.19× |
| Current ratio | 1.04× | 1.29× |
| Revenue CAGR 5y | 3.2% | 3.4% |
| Profit CAGR 5y | −7.1% | −0.7% |
DVA bills 1.2× the revenue of DGX, and DGX keeps more of each dollar of revenue as profit (9.0% against 5.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | DGX | DVA |
|---|---|---|
| FY2025 | $11.0B | $13.6B |
| FY2024 | $9.9B | $12.8B |
| FY2023 | $9.3B | $12.1B |
| FY2022 | $9.9B | $11.6B |
| FY2021 | $10.8B | $11.6B |
| FY2020 | $9.4B | $11.6B |
| FY2019 | $7.7B | $11.4B |
| FY2018 | $7.5B | $10.7B |
| FY2017 | $7.4B | $10.1B |
| FY2016 | $7.2B | $9.7B |
Net income by year
Bottom line
| Fiscal year | DGX | DVA |
|---|---|---|
| FY2025 | $992.0M | $746.8M |
| FY2024 | $871.0M | $936.3M |
| FY2023 | $854.0M | $691.5M |
| FY2022 | $946.0M | $560.4M |
| FY2021 | $2.0B | $978.5M |
| FY2020 | $1.4B | $773.6M |
| FY2019 | $858.0M | $811.0M |
| FY2018 | $736.0M | $159.4M |
| FY2017 | $772.0M | $663.6M |
| FY2016 | $645.0M | $879.9M |
Advertisement
AdSense · Rectangle 336×280